Literature DB >> 14668065

Platelet monoamine oxidase B activity changes across 31 days of smoking abstinence.

David G Gilbert1, Yantao Zuo, Ronald A Browning, Todd M Shaw, Norka E Rabinovich, Aline M Gilbert-Johnson, Louisette Plath.   

Abstract

Although recent studies demonstrate that tobacco cigarette smoke substantially inhibits both central nervous system and blood platelet monoamine oxidase (MAO) activity, little is known about the time course of MAO increases after smoking cessation. Therefore, changes in platelet MAO-B activity and mood were assessed before and at multiple times after quitting smoking. Quitting smoking was associated with a significant (22%) increase in MAO activity by day 3 and with a maximum increase (about 50%) by day 10 that was maintained through day 31 of abstinence. However, abstinence-related increases in depressive mood peaked at day 2 of abstinence, a week more rapidly than the peak increase in MAO-B activity. Neither mood nor MAO-B activity returned to baseline or smoking control levels across the 31-day abstinence period. The asynchrony of increased negative affect and MAO-B activity during the first few days of abstinence may reflect any of several possibilities. First, the duration of the platelet life cycle may not reflect central MAO-B or MAO-A activity. Second, MAO-B may not contribute to or index mood changes during the first days of abstinence though it may contribute to protracted abstinence-induced negative affect. These findings are discussed in terms of the hypothesis that platelet MAO activity reflects central nervous system MAO changes that promote increased depressive affect resulting from smoking abstinence.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14668065     DOI: 10.1080/14622200310001614575

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  7 in total

1.  A selective reversible monoamine oxidase B inhibitor in smoking cessation: effects on its own and in association with transdermal nicotine patch.

Authors:  Ivan Berlin; Ian M Hunneyball; Doris Greiling; Stephen P Jones; Hermann Fuder; Hans-Detlev Stahl
Journal:  Psychopharmacology (Berl)       Date:  2012-03-27       Impact factor: 4.530

2.  Negative affect subtypes and craving differentially predict long-term cessation success among smokers achieving initial abstinence.

Authors:  Yantao Zuo; Norka E Rabinovich; David G Gilbert
Journal:  Psychopharmacology (Berl)       Date:  2016-12-27       Impact factor: 4.530

Review 3.  Monoamine oxidase inhibition for tobacco pharmacotherapy.

Authors:  T P George; A H Weinberger
Journal:  Clin Pharmacol Ther       Date:  2007-12-19       Impact factor: 6.875

4.  Patterns of change in withdrawal symptoms, desire to smoke, reward motivation and response inhibition across 3 months of smoking abstinence.

Authors:  Lynne Dawkins; Jane H Powell; Alan Pickering; John Powell; Robert West
Journal:  Addiction       Date:  2009-03-13       Impact factor: 6.526

Review 5.  Mechanism-based medication development for the treatment of nicotine dependence.

Authors:  Zheng-xiong Xi; Krista Spiller; Eliot L Gardner
Journal:  Acta Pharmacol Sin       Date:  2009-05-11       Impact factor: 6.150

Review 6.  Monoamine oxidase inhibition in cigarette smokers: From preclinical studies to tobacco product regulation.

Authors:  Alan F Sved; Jillian J Weeks; Anthony A Grace; Tracy T Smith; Eric C Donny
Journal:  Front Neurosci       Date:  2022-08-16       Impact factor: 5.152

7.  Smoking induces long-lasting effects through a monoamine-oxidase epigenetic regulation.

Authors:  Jean-Marie Launay; Muriel Del Pino; Gilles Chironi; Jacques Callebert; Katell Peoc'h; Jean-Louis Mégnien; Jacques Mallet; Alain Simon; Francine Rendu
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.